Medical, surgical and interventional management of hypertrophic cardiomyopathy with obstruction

Current Treatment Options in Cardiovascular Medicine

Volumn 14, Issue 6, 2012, Pages 665-678

  Elmariah, Sammy ^b   Fifer, Michael A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

Alcohol septal ablation; Atrial fibrillation; Beta blocker; Calcium channel blocker; Disopyramide; Hypertrophic obstructive cardiomyopathy; Pacemaker; Septal myectomy; Septal reduction therapy; Sudden cardiac death

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CIBENZOLINE; CYANOACRYLATE; DABIGATRAN; DILTIAZEM; DISOPYRAMIDE; PERHEXILINE; PILSICAINIDE; PROPRANOLOL; RIVAROXABAN; SODIUM CHANNEL BLOCKING AGENT; VERAPAMIL; WARFARIN;

ABLATION THERAPY; ALCOHOL SEPTAL ABLATION; ALOPECIA; ARTICLE; BRADYCARDIA; COMPLICATION; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISEASE CONTROL; DRUG COST; DRUG SAFETY; EDEMA; ENDOCARDIAL RADIOFREQUENCY ABLATION OF SEPTAL HYPERTROPHY; FATIGUE; GASTROINTESTINAL SYMPTOM; GLUE SEPTAL ABLATION; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE OUTFLOW TRACT; HEART SURGERY; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; HYPOTENSION; HYPOVOLEMIA; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; IMPOTENCE; LIFESTYLE MODIFICATION; LIVER TOXICITY; MUSCLE RESECTION; PACEMAKER; QT INTERVAL; RADIOFREQUENCY ABLATION; SCREENING; SEPTAL MYECTOMY; SEPTAL REDUCTION THERAPY; SIDE EFFECT; SUDDEN DEATH; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; XEROSTOMIA;

EID: 84870289259     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-012-0206-5     Document Type: Article

References (50)

1. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med. 1997;336:775-85. (Pubitemid 27113973)
2. Gupta RM, Weiner RB, Baggish AL, Fifer MA. Still a kid at heart: hypertrophic cardiomyopathy in the elderly. Circulation. 2011;124:857-63.
3. Braunwald E, Brockenbrough EC, Morrow AG. Hypertrophic subaortic stenosis-a broadened concept. Circulation. 1962;26:161-5.
4. Dimitrow PP, Cotrim C, Cheng TO. Importance of upright posture during exercise in detection of provocable left ventricular outflow tract gradient in hypertrophic cardiomyopathy. Am J Cardiol. 2011;108:614.
5. Fifer MA, Vlahakes GJ. Management of symptoms in hypertrophic cardiomyopathy. Circulation. 2008;117:429-39.
6. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:e269-367.
7. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104:2517-24. (Pubitemid 33107372)
8. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:e783-831.
9. Frank MJ, Abdulla AM, Canedo MI, Saylors RE. Long-term medical management of hypertrophic obstructive cardiomyopathy. Am J Cardiol. 1978;42:993-1001.
10. Fifer MA, O'Gara PT, McGovern BA, Semigran MJ. Effects of disopyramide on left ventricular diastolic function in hypertrophic cardiomyopathy. Am J Cardiol. 1994;74:405-8. (Pubitemid 24253486)
11. Kajimoto K, Imai T, Minami Y, Kasanuki H. Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline. Am J Cardiol. 2010;106:1307-12.
12. Ball W, Ivanov J, Rakowski H, Wigle ED, Linghorne M, Ralph-Edwards A, et al. Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment. J Am Coll Cardiol. 2011;58:2313-21.
13. Agarwal S, Tuzcu EM, DesaiMY, Smedira N, Lever HM, Lytle BW, et al.Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;55:823-34.
14. Leonardi RA, Kransdorf EP, Simel DL, Wang A. Metaanalyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment. Circ Cardiovasc Interv. 2010;3:97-104.
15. Fifer MA, Sigwart U. Controversies in cardiovascular medicine. Hypertrophic obstructive cardiomyopathy: alcohol septal ablation. Eur Heart J. 2011;32:1059-64.
16. Cecchi F, Olivotto I, Nistri S, Antoniucci D, Yacoub MH. Midventricular obstruction and clinical decision-making in obstructive hypertrophic cardiomyopathy. Herz. 2006;31:871-6. (Pubitemid 46028460)
17. Chen J, Nagaraj H, Bhambhani P, Kliner DE, Soman P, Garcia EV, et al. Effect of alcohol septal ablation in patients with hypertrophic cardiomyopathy on left-ventricular mechanical dyssynchrony Abstract: assessed by phase analysis of gated SPECT myocardial perfusion imaging. Int J Cardiovasc Imaging. 2011 doi:10.1007/s10554-011-9942-y.
18. Timmer SA, Knaapen P, Germans T, Dijkmans PA, Lubberink M, Ten Berg JM, et al. Effects of alcohol septal ablation on coronary microvascular function and myocardial energetics in hypertrophic obstructive cardiomyopathy. Am J Physiol Heart Circ Physiol. 2011;301:H129-37.
19. Jensen MK, Almaas VM, Jacobsson L, Hansen PR, Havndrup O, Aakhus S, et al. Long-term outcome of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: a Scandinavian multicenter study. Circ Cardiovasc Interv. 2011;4:256-65.
20. Nagueh SF, Groves BM, Schwartz L, Smith KM, Wang A, Bach RG, et al. Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. A multicenter North American registry. J Am Coll Cardiol. 2011;58:2322-8.
21. Geske JB, Sorajja P, Ommen SR, Nishimura RA. Variability of left ventricular outflow tract gradient during cardiac catheterization in patients with hypertrophic cardiomyopathy. JACC Cardiovasc Interv. 2011;4:704-9.
22. Almasood A, Garceau P, Woo A, Rakowski H, Schwartz L, Overgaard CB. Time to significant gradient reduction following septal balloon occlusion predicts the magnitude of final gradient response during alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. JACC Cardiovasc Interv. 2011;4:1030-4.
23. Ghersin E, Soto V, Heldman AW. Multidetector computerized tomography can guide and document alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation. 2011;123:e5-7.
24. Krishnaswamy A, Tuzcu EM, Kapadia SR. Use of intraprocedural CT imaging to guide alcohol septal ablation of hypertrophic cardiomyopathy in the cardiac catheterization laboratory. Catheter Cardiovasc Interv. 2011.
25. Spratt JC, Langrish JP. Identifying the target septal perforator prior to alcohol septal ablation in hypertrophic obstructive cardiomyopathy: a new application for computed tomography coronary angiography. Heart. 2011;97:1718-9.
26. Veselka J, Duchonova R, Prochazkova S, Palenickova J, Sorajja P, Tesar D. Effects of varying ethanol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy on early hemodynamic changes. Am J Cardiol. 2005;95:675-8. (Pubitemid 40255269)
27. Fifer MA, Palacios I, Sanborn DMY, Sigwart U. Hypertrophic cardiomyopathy. In: Lanzer P, editor. Catheter-based Cardiovascular Interventions. Springer; In press.
28. Cuisset T, Franceschi F, Prevot S, Ansaldi S, Habib G, Pankert M, et al. Transradial approach and subclavian wired temporary pacemaker to increase safety of alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: the TRASA trial. Arch Cardiovasc Dis. 2011;104:444-9
29. Guo R, Qian J, Yang Y, Zhu Q, Liu D, Deng C, et al. A new strategy for septal ablation with transendocardial ethanol injection using multifunctional intracardiac echocardiography catheter: a feasibility study in canines. Catheter Cardiovasc Interv. 2011;78:316-23.
30. Sorajja P, Valeti U, Nishimura RA, Ommen SR, Rihal CS, Gersh BJ, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2008;118:131-9.
31. Chen AA, Palacios IF, Mela T, Yoerger DM, Picard MH, Vlahakes G, et al. Acute predictors of subacute complete heart block after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2006;97:264-9. (Pubitemid 43139249)
32. Schaff HV, Dearani JA, Ommen SR, Sorajja P, Nishimura RA. Expanding the indications for septal myectomy in patients with hypertrophic cardiomyopathy: Results of operation in patients with latent obstruction. J Thorac Cardiovasc Surg. 2012;143:303-9.
33. Brown ML, Schaff HV, Dearani JA, Li Z, Nishimura RA, Ommen SR. Relationship between left ventricular mass, wall thickness, and survival after subaortic septal myectomy for hypertrophic obstructive cardiomyopathy. J Thorac Cardiovasc Surg. 2011;141:439-43.
34. Rothman RD, Sadfiia MA, Lowry PA, Mela T, Abbara S, O'Callaghan C, et al. Risk stratification for sudden cardiac death after septal myectomy. J Card Cases. 2011;3:e65-7.
35. Nasseri BA, Stamm C, Siniawski H, Kukucka M, Komoda T, Delmo Walter EM, et al. Combined anterior mitral valve leaflet retention plasty and septal myectomy in patients with hypertrophic obstructive cardiomyopathy. Eur J Cardiothorac Surg. 2011;40:1515-20.
36. Ashikhmina EA, Schaff HV, Ommen SR, Dearani JA, Nishimura RA, Abel MD. Intraoperative direct measurement of left ventricular outflow tract gradients to guide surgical myectomy for hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 2011;142:53-9.
37. Kim JH, Malhotra R, Chiampas G, d'Hemecourt P, Troyanos C, Cianca J, et al. Cardiac arrest during long-distance running races. N Engl J Med. 2012;366:130-40.
38. Maron BJ, Chaitman BR, Ackerman MJ, Bayes de Luna A, Corrado D, Crosson JE, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation. 2004;109:2807-16. (Pubitemid 38744555)
39. Berruezo A, Vatasescu R, Mont L, Sitges M, Perez D, Papiashvili G, et al. Biventricular pacing in hypertrophic obstructive cardiomyopathy: a pilot study. Hear Rhythm. 2011;8:221-7.
40. Bos JM, Maron BJ, Ackerman MJ, Haas TS, Sorajja P, Nishimura RA, et al. Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy. Am J Cardiol. 2010;106:1481-6.
41. O'Mahony C, Lambiase PD, Quarta G, Cardona M, Calcagnino M, Tsovolas K, et al. The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy. Heart. 2012;98:116-25.
42. You JJ, Woo A, Ko DT, Cameron DA, Mihailovic A, Krahn M. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for theprimary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. Am Heart J. 2007;154:899-907. (Pubitemid 350010926)
43. Goldenberg I, Moss AJ, Maron BJ, Dick AW, Zareba W. Cost-effectiveness of implanted defibrillators in young people with inherited cardiac arrhythmias. Ann Noninvasive Electrocardiol. 2005;10:67-83. (Pubitemid 44933556)
44. Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45:1251-8. (Pubitemid 40523146)
45. McCready JW, Smedley T, Lambiase PD, Ahsan SY,Segal OR, Rowland E, et al. Predictors of recurrence following radiofrequency ablation for persistent atrial fibrillation. Europace. 2011;13:355-61.
46. Force T, Bonow RO, Houser SR, Solaro RJ, Hershberger RE, Adhikari B, et al. Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. Circulation. 2010;122:1130-3.
47. Abozguia K, Elliott P, McKenna W, Phan TT, Nallur-Shivu G, Ahmed I, et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation. 2010;122:1562-9.
48. Oto A, Aytemir K, Okutucu S, Kaya EB, Deniz A, Cil B, et al. Cyanoacrylate for septal ablation in hypertrophic cardiomyopathy. J Interv Cardiol. 2011;24:77-84.
49. Lawrenz T, Borchert B, Leuner C, Bartelsmeier M, Reinhardt J, Strunk-Mueller C, et al. Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy: acute results and 6 months' follow-up in 19 patients. J Am Coll Cardiol. 2011;57:572-6.
50. Sreeram N, Emmel M, de Giovanni JV. Percutaneous radiofrequency septal reduction for hypertrophic obstructive cardiomyopathy in children. J Am Coll Cardiol. 2011;58:2501-10.